Tag - ELOX

Developments

Eloxx announces first patients dosed in study of exaluren in NMAS

Eloxx Pharmaceuticals (NASDAQ: ELOX) has announced that the first two patients have been dosed in its Phase 2b EXACT Study evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS). According to...

September 11, 2026

Developments

Eloxx Pharma ELX-02 granted FDA orphan drug designation for cystic fibrosis

Eloxx Pharmaceuticals’ (NASDAQ:ELOX) ELX-02 received FDA orphan drug designation for the treatment of cystic fibrosis (CF). ELX-02 is a small molecule designed to restore production of CF transmembrane conductance...

August 5, 2020

Markets

HCW slashes Eloxx Pharma PT to $3 from $10

H.C. Wainwright slashed its price target for Eloxx Pharmaceuticals (NASDAQ:ELOX) to $3 from $10 and retained its “neutral” rating, saying the strength of the company’s ELX-02 program in cystic fibrosis is yet to be...

March 6, 2020

Markets

Janney starts Eloxx Pharma at buy; fair value estimate $14

Janney launched coverage of Eloxx Pharmaceuticals (NASDAQ:ELOX) with a “buy” rating and fair value estimate of $14. The stock closed at $5.97 on Sept. 5. Eloxx’s pipeline is focused on genetic diseases caused by...

September 6, 2019

Developments

Eloxx Pharma initiates Phase 2 cystinosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX) initiated a Phase 2 trial of ELX-02 for the treatment of nephropathic cystinosis. Cystinosis is a genetic disease caused by a mutation in the cystinosin gene, which limits production...

August 6, 2019

Developments

Eloxx Pharma IND cleared for Phase 2 cystic fibrosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported that the FDA cleared its IND for a Phase 2 trial of ELX-02 in patients with cystic fibrosis (CF). ELX-02 is a small molecule designed to restore production of CF...

July 31, 2019

Tag - ELOX

Eloxx announces first patients dosed in study of exaluren in NMAS

Eloxx Pharma ELX-02 granted FDA orphan drug designation for cystic fibrosis

HCW slashes Eloxx Pharma PT to $3 from $10

Janney starts Eloxx Pharma at buy; fair value estimate $14

Eloxx Pharma initiates Phase 2 cystinosis trial

Eloxx Pharma IND cleared for Phase 2 cystic fibrosis trial

Subscribe